Safinamide continues to show promise in PD
This article was originally published in Scrip
Executive Summary
Despite failing to hit the primary endpoint in its latest study safinamide, the small molecule monoamine oxidase B inhibitor being developed by Merck Serono and Newron Pharmaceuticals, looks to still be on course to becoming an effective treatment of Parkinson's disease.